Patents Represented by Attorney Daryl B. Winter
-
Patent number: 6040136Abstract: A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered binding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.Type: GrantFiled: September 3, 1997Date of Patent: March 21, 2000Assignee: Genentech, Inc.Inventors: Lisa J. Garrard, Dennis J. Henner, Steven Bass, Ronald Greene, Henry B. Lowman, James A. Wells, David J. Matthews
-
Patent number: 6034216Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.Type: GrantFiled: April 8, 1998Date of Patent: March 7, 2000Assignee: Genentech Inc.Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson
-
Patent number: 5879673Abstract: The present invention is directed to the surprising and unexpected finding that biologically active thrombopoietin materials can be administered with substantial therapeutic effect at dosage rates commensurate with previously reported administration of such materials, but in a single or low-multiple daily administration. Thus, the predicate of the present invention relates to the reversal of thrombocytopenia by administering to a patient having or in need of such treatment a single or low-multiple daily dose of a therapeutically effective amount of a thrombopoietin. The preferable dose of the active material ranges from about 1 to about 10 .mu.g/kg body weight.Type: GrantFiled: August 28, 1996Date of Patent: March 9, 1999Assignee: Genentech, Inc.Inventor: Griffith Roger Thomas
-
Patent number: 5846765Abstract: A method for identifying and selecting novel substrates for enzymes is provided. The method comprises constructing a gene fusion comprising DNA encoding a polypeptide fused to DNA encoding a substrate peptide, which in turn is fused to DNA encoding at least a portion of a phage coat protein. The DNA encoding the substrate peptide is mutated at one or more codons thereby generating a family of mutants. The fusion protein is expressed on the surface of a phagemid particle and subjected to chemical or enzymatic modification of the substrate peptide. Those phagemid particles which have been modified are then separated from those that have not.Type: GrantFiled: May 16, 1995Date of Patent: December 8, 1998Assignee: Genentech, Inc.Inventors: David J. Matthews, James A. Wells, Mark J. Zoller
-
Patent number: 5843941Abstract: Benzodiazepine derivatives represented by the structure below are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases foe which inhibition of the ras farnesyl:protein transferase as indicated.Type: GrantFiled: September 26, 1994Date of Patent: December 1, 1998Assignees: Genentech, Inc., Board of Regents University of TexasInventors: James C. Marsters, Jr., Michael S. Brown, Craig W. Crowley, Joseph L. Goldstein, Guy L. James, Robert S. McDowell, David Oare, Thomas E. Rawson, Mark Reynolds, Todd C. Somers
-
Patent number: 5834598Abstract: A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered binding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.Type: GrantFiled: June 5, 1995Date of Patent: November 10, 1998Assignee: Genentech, Inc.Inventors: Henry B. Lowman, James A. Wells
-
Patent number: 5830647Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocyte progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.Type: GrantFiled: April 26, 1995Date of Patent: November 3, 1998Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. de Sauvage
-
Patent number: 5821047Abstract: A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered binding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.Type: GrantFiled: June 5, 1995Date of Patent: October 13, 1998Assignee: Genentech, Inc.Inventors: Lisa J. Garrard, Dennis J. Henner, Steven Bass, Ronald Greene, Henry B. Lowman, James A. Wells, David J. Matthews
-
Patent number: 5798337Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.Type: GrantFiled: November 16, 1994Date of Patent: August 25, 1998Assignee: Genentech, Inc.Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson
-
Patent number: 5780279Abstract: A method for identifying and selecting novel substrates for enzymes is provided. The method comprises constructing a gene fusion comprising DNA encoding a polypeptide fused to DNA encoding a substrate peptide, which in turn is fused to DNA encoding at least a portion of a phage coat protein. The DNA encoding the substrate peptide is mutated at one or more codons thereby generating a family of mutants. The fusion protein is expressed on the surface of a phagemid particle and subjected to chemical or enzymatic modification of the substrate peptide. Those phagemid particles which have been modified are then separated from those that have not.Type: GrantFiled: April 5, 1995Date of Patent: July 14, 1998Assignee: Genentech, Inc.Inventors: David J. Matthews, James A. Wells, Mark J. Zoller
-
Patent number: 5756452Abstract: A peptide containing the tripeptide recognition sequences RGD or KGD in a cycle and an exocyclic group bearing a positive charge is provided. The compound is provided in therapeutic form for administration to a mammal and exhibits high specificity and potency as a platelet aggregation inhibitor without undesireable side effects.Type: GrantFiled: December 6, 1995Date of Patent: May 26, 1998Assignee: Genentech, Inc.Inventors: John P. Burnier, Thomas Gadek, Robert S. McDowell
-
Patent number: 5750373Abstract: A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered binding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.Type: GrantFiled: April 30, 1993Date of Patent: May 12, 1998Assignee: Genentech, Inc.Inventors: Lisa J. Garrard, Dennis J. Henner, Steven Bass, Ronald Greene, Henry B. Lowman, James A. Wells, David J. Matthews
-
Patent number: 5736135Abstract: A screening method for the selection of mutagenized proteins that are normally secreted by cells is described. The method includes the development of a cloning vector for the expression of secretory proteins as fusion proteins on the cell surface of transfected mammalian cells. The secreted protein is displayed on the cell surface by fusion with the glycophospholipid membrane anchor of decay accelerating factor (DAF). Tissue-type plasminogen activator (t-PA), which is normally secreted, is used as a model protein. PCR mutagenesis is used to generate random mutations within the Kringle 1 (K1) domain of t-PA. Fluorescence activated cell sorting (FACS) is employed to screen for t-PA mutants possessing a loss of an epitope to a specific Mab, whose nonlinear binding domains overlap with the t-PA clearance receptor contact regions novel t-PA mutants designated N115S, N1425S, and K159R were discovered by this method.Type: GrantFiled: February 13, 1995Date of Patent: April 7, 1998Assignee: Genentech, Inc.Inventors: David V. Goeddel, Glenn C. Rice, David W. H. Leung
-
Patent number: 5716951Abstract: A tricylic benzodiazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.Type: GrantFiled: May 8, 1995Date of Patent: February 10, 1998Assignee: Genentech, Inc.Inventors: Brent K. Blackburn, Kirk Robarge, Todd C. Somers
-
Patent number: 5705890Abstract: A tricylic benzodiazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.Type: GrantFiled: September 26, 1994Date of Patent: January 6, 1998Assignee: Genentech, Inc.Inventors: Brent K. Blackburn, Kirk Robarge, Todd C. Somers
-
Patent number: 5674863Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.Type: GrantFiled: May 26, 1995Date of Patent: October 7, 1997Assignee: Genentech, Inc.Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
-
Patent number: 5674865Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.Type: GrantFiled: May 26, 1995Date of Patent: October 7, 1997Assignee: Genentech, Inc.Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
-
Patent number: 5663166Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.Type: GrantFiled: May 26, 1995Date of Patent: September 2, 1997Assignee: Genentech, Inc.Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
-
Patent number: 5589363Abstract: DNA enclosing a tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.blll.sub.a inhibitor.Type: GrantFiled: May 20, 1994Date of Patent: December 31, 1996Assignee: Genentech, Inc.Inventors: Soumitra Roy, Gordon A. Vehar
-
Patent number: 5565449Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.Type: GrantFiled: May 26, 1995Date of Patent: October 15, 1996Assignee: Genentech, Inc.Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge